Mini Review

Self-assembling protein nanoparticles in the design of vaccines

Jacinto López-Sagaseta*, Enrico Malito, Rino Rappuoli, Matthew J. Bottomley

GlaxoSmithKline Vaccines S.r.l., Via Fiorentina 1, 53100 Siena, Italy

ABSTRACT

For over 100 years, vaccines have been one of the most effective medical interventions for reducing infectious diseases, and are estimated to save millions of lives globally each year. Nevertheless, many diseases are not yet preventable by vaccination. This large unmet medical need demands further research and the development of novel vaccines with high efficacy and safety. Compared to the 19th and early 20th century vaccines that were made of killed, inactivated, or live-attenuated pathogens, modern vaccines containing isolated, highly purified antigenic protein subunits are safer but tend to induce lower levels of protective immunity. One strategy to overcome the latter is to design antigen nanoparticles: assemblies of polypeptides that present multiple copies of subunit antigens in well-ordered arrays with defined orientations that can potentially mimic the repetitiveness, geometry, size, and shape of the natural host-pathogen surface interactions. Such nanoparticles offer a collective strength of multiple binding sites (avidity) and can provide improved antigen stability and immunogenicity. Several exciting advances have emerged lately, including preclinical evidence that this strategy may be applicable for the development of innovative new vaccines, for example, protecting against influenza, human immunodeficiency virus, and respiratory syncytial virus. Here, we provide a concise review of a critical selection of data that demonstrate the potential of this field. In addition, we highlight how the use of self-assembling protein nanoparticles can be effectively combined with the emerging discipline of structural vaccinology for maximum impact in the rational design of vaccine antigens.

© 2015 López-Sagaseta et al. Published by Elsevier B.V. on behalf of the Research Network of Computational and Structural Biotechnology. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

1. Introduction

Vaccines are among the most outstanding achievements in human medical history. Through their power to prevent or reduce the burden of infectious diseases they make an enormous global impact by improving the life quality of both humans and animals. Vaccines may save up to three million children’s lives and up to six million total lives each year [1,2]. In addition to their contribution to an increased survival rate, vaccines are also an essential medical tool to protect against cancers and devastating sequelae derived from viral and bacterial infections, such as human papillomavirus (HPV) or meningitis, allergies, autoimmune diseases, or even drug dependencies.

However, there are many important pathogens against which vaccines do not yet exist, and some current vaccines could be improved. For example, some vaccines do not protect against all circulating strains of a pathogen because many microbes have developed sophisticated mechanisms to escape the host immune system. Mutations on the antigens of microbes such as influenza (flu), human immunodeficiency virus (HIV), or meningococcus constitute a rapidly changing ‘disguise’ to avoid recognition by trained immune cells that might otherwise prevent infection or disease. Further, some vaccine antigens do not elicit sufficiently durable or potent immunity. In addition to this, the rise of drug-resistant pathogenic entities such as those causing shigellosis demands our attention in the search for proficient vaccines [3]. Therefore, a major research focus is to seek ways to boost vaccine-induced host protection against pathogens, by developing novel antigens that evoke a more robust and protective immune response.

Many effective vaccines developed in the past used live-attenuated strains of a pathogen, or inactivated killed pathogens [4]. Live-attenuated vaccine strains are typically highly immunogenic, but carry inherent safety concerns, given the potential of these weakened viral particles to revert into disease-causing viruses. Additionally, mutagenic events within the host organism may generate more virulent strains. Conversely, while inactivated or killed vaccine pathogens cannot replicate nor revert into more virulent forms, they tend to stimulate a weaker immune reaction, and thus may require the administration of multiple dosages, an important practical limitation. An effective way to address these limitations has gradually emerged through studies of self-assembling proteins, which can be used as nanoparticles mediating multi-copy antigen display.

One of the earliest examples of a self-associating protein particle was reported in the 1950s: a protein extracted from the tobacco mosaic virus (TMV) was found to form rod-shaped particles, which morphologically...
resembled the original TMV but which did not contain genetic material [5]. Later, in the 1970s, the hepatitis B virus (HBV) surface antigen (HBsAg) was purified from infected human serum [6]. Electron microscopy (EM) and ultraviolet absorption studies revealed that HBsAg formed spherical particles with an average diameter of ~22 nm and which, importantly, like the TMV protein particle, lacked nucleic acid and hence were non-infectious. Preparations of such virus-derived ‘nanoparticles’ formed the first efficacious HBV vaccine, licensed in 1981 [7], and represented a milestone that created a new focus in the field of vaccinology. Indeed, antigen nanoparticles, first exemplified by HBsAg, have now emerged as a leading strategy in the development of safe and potent vaccines.

What are the advantages of nanoparticle antigens? Key parameters governing the elicitation of an efficient immune response to a microbe include both antigen density and distribution on the pathogen surface [8]. B- and T-cell stimulation and activation, and the subsequent secretion of antigen-specific antibodies by plasma cells, rely on effective cross-linking between B-cell surface immunoglobulins (the B-cell receptor, BCR) and the recognition pattern presented by the pathogen. The high density and structurally ordered antigenic array presented by a nanoparticle provides a molecular scenario where multiple binding events occur simultaneously between the nanoparticle and the host cell BCRs (Fig. 1). This multivalent molecular and cellular setting favors the fruitful network of stimulatory interactions, as opposed to the weaker effect of monovalent binding afforded by single soluble recombinant antigens. Indeed, the high avidity for the nanoparticle provided by the multivalent interaction constitutes a critical step in the induction of a potent immune reaction (Fig. 1). Because of these advantageous

Fig. 1. Multivalent nanoparticles favor the generation of potent, long-lived immunoprotection in germinal centers. Recombinant nanoparticles loaded with the desired antigen are designed thoroughly to present multiple copies of a pathogen epitope in a highly ordered manner on the surface of a self-assembling nanoparticle. As opposed to single recombinant antigens that provide brief half-life 1:1 interactions with the BCRs (A), the polyclonal nature, i.e. avidity, of the interaction with the nanoparticle enables tighter and prolonged bindings: the dissociation of one antigen molecule can be compensated by the binding of a new antigen molecule or re-association with a new BCR (B). This scenario enables the clustering of BCRs for multiple and simultaneous engagement with the antigen epitopes. Thus, the B-cell traps the antigen-loaded nanoparticle to establish a durable, localized and strong recognition that translates into B-cell intracellular signaling, internalization and processing of the antigen for presentation, via molecules of the MHC complex, to the T follicular helper cells (Tfh) within the germinal centers. This new recognition evokes the secretion of regulatory cytokines by the Tfh cell and ultimately the evolution of B cells into plasma cells that can secrete antigen-specific neutralizing Abs.
immunological and physicochemical properties, and their suitability for large-scale manufacturing via Escherichia coli (E. coli) or eukaryotic systems, nanoparticles are at the forefront of new vaccine therapeutics.

A variety of naturally occurring proteins can self-assemble into nanoparticles that are highly symmetric, stable, and structurally organized, with diameters of 10–150 nm [9,10], a highly suitable size range for optimal interactions with various cells of the immune system [8,11]. These nanoparticles normally play diverse physiological roles, but are of particular interest in the context of vaccine design because they can be used as self-assembling platforms for the display of an arranged and well-ordered matrix of a particular immunogen, thereby mimicking the repetitive surface architecture of a natural microbe, e.g. a spherical virus capsid [12].

While many natural proteins have acquired self-assembling properties during evolution [13], the de novo engineering of protein assemblies is challenging. Early proposals to rationally perform atomic and molecular manipulations to generate interesting new materials were mentioned by Richard Feynman in 1960 [14,15]. Later, the idea of combining proteins as building blocks into higher-order structures via self-assembly was advanced [15,16]. More recently, the feasibility of designing self-assembling proteins has improved via new computational approaches [17]. Consequently, using natural or engineered protein nanoparticle scaffolds, vaccinologists can now aim to add heterologous epitopes or antigens onto the ‘plain’ nanoparticle, thus representing a limitless source of possible ‘chimeric’ nanoparticle antigens. Such chimeric nanoparticles can be obtained by self-assembly, or by covalent chemical attachment of an antigen to a nanoparticle.

Since the emergence of nanoparticle vaccine antigens in the 1970s, numerous attempts to generate plain or chimeric nanoparticles with scaffolds from many origins have been described. Some of these are virus-like particles (VLPs) composed of single or multiple viral antigens, in some cases anchored in a lipid bilayer. Structural proteins from different microorganisms have served as templates for the production of such nanoparticles and for the presentation of immunogenic epitopes: the protein pII of the filamentous phage ϕ1 [18], the Ty component from Saccharomyces cerevisiae [19], the surface and core antigens of the hepatitis B virus [20,21], surface or coat proteins of bluetongue virus [22], human parvovirus B19 [23], tobacco mosaic virus [24], the Picornaviridae virus [25], Sindbis virus [26], and papillomavirus [27,28] are just some examples. This mini-review will focus on a subset of such studies. We also aim to draw the reader’s attention to how we believe the design of future candidate antigens can be optimized by combining structural vaccinology and nanoparticle research. Structural vaccinology is an emerging discipline that uses insights from structural and computational biology studies with neighboring fields such as formulation science, immunology, animal studies, and serology in order to design, evaluate, optimize, and deliver leading candidate vaccine antigens [29,30]. As a minor note, synthetic nanoparticles made from non-polypeptide polymers, metals, or other solid supports, and the use of encapsulating particles as vaccine delivery systems are beyond the scope of the current review, and the reader is directed to alternative sources [31–33].

2. Biochemistry and applications of bionanoparticle antigens

2.1. Viral proteins and virus-like particles (VLPs)

Many viruses encode proteins that form stable nanoparticle structures, which self-assemble in infected host cells in order to package the viral genomes as a pre-requisite for propagation. However, if scaffold proteins are assembled in the absence of genetic material, then non-infectious non-replicating virus-like particles (VLPs) that closely resemble intact virions can be obtained. Consequently, viral nanoparticles or VLPs composed of one, or a few, recombinant self-assembling proteins were among the first antigen-nanoparticle candidates, some of which have indeed been developed into successfully marketed vaccines [4]. Indeed, the earliest VLPs were relatively simply obtained by self-assembly of single recombinant HBV or HPV capsid proteins. After excellent results obtained with these first ‘plain’ VLPs, several ‘chimeric’ VLPs were explored as platforms for the display of heterologous epitopes or antigens. Here, notable examples from both categories are discussed. We will also briefly discuss the more complex VLPs representing enveloped viruses. In contrast to VLPs made from highly purified protein capsids, enveloped VLPs (virosomes) are assembled by budding from the host cell membrane. More extensive reviews of viral or VLP vaccines, with a focus on the challenges of their industrial development and manufacturing, can be found elsewhere [34,35].

In the second half of the 20th century, the first genetically engineered vaccine was developed by cloning the VP1 capsid protein of the foot-and-mouth disease virus (FMDV), which was demonstrated to be a safe, stable and effective polypeptide vaccine for cattle and swine [36]. The breakthrough of the genetic FMDV animal vaccine, coupled with the discovery of the HBsAg vaccine antigen purified from human serum, stimulated the search for a safe, genetic in vitro-produced vaccine to protect humans against HBV. In 1986, licensure was obtained for the first human vaccine based on a recombinant protein subunit antigen (HBsAg), which self-assembles into nanoparticles [37,38]. Although these assemblies form nanoparticles, they do not very closely resemble the intact HBV virion and thus are not fully considered VLPs. Nevertheless, recombinant HBsAg nanoparticles are included in two safe and efficacious vaccines (marketed as Engerix-B [39] and Recombivax-HB), now globally implemented to protect against HBV.

Perhaps the first real VLP human vaccine is the successful story of two similar vaccines protecting against HPV infection, a major cause of genital diseases and, especially, cervical cancer [40]. Both vaccines were launched in the first decade of the 21st century (marketed as Cervarix and Gardasil) and contain recombinant HPV L1 major capsid protein VLPs [27,28]. The development of these vaccines followed work in the 1980s, when the first reports emerged describing the self-assembly of recombinant forms of the major capsid proteins of several viruses, including hepatitis B [37], polyoma [41], and parvovirus [42]. Studies in the early 1990s then revealed that recombinant L1 from bovine and human papillomaviruses could self-assemble into empty capsid-like nanoparticles of ~50 nm diameter and, importantly, L1 nanoparticles could raise high-titer neutralizing antibodies in animals, with an immunogenicity profile similar to that of infectious HPV virions [43,44]. Notably, the denatured non-assembled form of L1 did not induce neutralizing antibodies [40], highlighting the importance of the correct nanoparticulate structure of the protective epitopes in the L1 VLPs.

Several high-resolution crystal structures of different HPV L1 proteins have been determined, revealing the molecular basis for their oligomerization into the pentameric assembly unit of the viral shell [45]. Further, cryoEM studies have enabled reconstructions of the entire HPV type 16 capsid alone or bound to neutralizing Fab fragments [46–48]. Together, these structural studies have provided a deep understanding of the HPV L1 structure, antigenic specificity, and assembly into nanoparticles. Such L1 VLPs derived from HPV types 16 and 18 (in the bivalent Cervarix) and additionally types 6, 11 (in the quadrivalent Gardasil), 31, 33, 45, 52, and 58 (in the nonavalent Gardasil 9) form the basis of safe and highly efficacious vaccines [49] (Table 1). Both HPV vaccines currently have relatively high production costs and their strain coverage efficacy is specific only for these L1 types included in the formulation, thus leaving room for improvement of potential second-generation vaccines. Nevertheless, the HPV L1 VLPs represent a shining example that encouraged the development and implementation of additional nanoparticle vaccines.

In addition to the research and clinical development of the HPV nanoparticle vaccines, numerous other viruses (for example, rotavirus [50], poliovirus [51], herpesvirus [52], and parvovirus [53]) have been used to generate non-infectious VLPs as vaccine candidates, although currently mostly without successful clinical development. However,
the increased understanding of the self-assembly of these nanoparticles and VLP production technology led to new opportunities in making chimeric VLPs that display heterologous epitopes or antigens attached to the VLP either by covalent modification (chemical cross-linking) or through genetic engineering, discussed further below.

The first viral nanoparticles to be discovered, efficiently produced recombinantly and characterized were those from HBV, composed either of the surface antigen (HBsAg) [37], as described above, or the core antigen (HBcAg) [54]. The HBcAg was first shown to self-assemble into particles of 24–31 nm diameter, which resembled the viral cores obtained from HBV-infected human liver, and which were highly immunogenic in animals. Later cryoEM studies revealed that HBcAg produced in *E. coli* self-assembles into two classes of differently sized nanoparticles of 300 Å and 360 Å diameter, corresponding to 180 or 240 protomers [55,56]. A landmark study by Brown and co-workers showed that a chimeric recombinant form of HBcAg genetically fused to the foreign FMDV peptide epitope could be produced in a viral expression system and self-assembled into nanoparticles displaying the FMDV epitope. This chimera was significantly more potent than the free FMDV peptide or the same peptide coupled to a β-galactosidase carrier and, was highly potent in raising neutralizing antibodies against both FMDV and HBV [20]. Many analogous studies were subsequently performed, for example, showing that a human rhinovirus peptide presented on the HBcAg particle was 100-fold more immunogenic than uncoupled peptide [57]. Overall, many such studies revealed a number of sites on HBV nanoparticles suitable for insertion and display of foreign epitopes, in order to ensure optimal presentation to the immune system. It also emerged that carrier-specific immunosuppression and pre-existing immunity to HBcAg did not significantly alter the immunogenicity of the chimeric particles, thus potentially allowing repeated immunizations with the same nanoparticle platform [58]. Collectively, these findings supported the use of HBcAg nanoparticles or similar VLPs as efficient scaffolds for the presentation of heterologous (‘foreign’) epitopes as vaccine antigens.

Indeed, in the long search for a vaccine against malaria, successful clinical trials have been performed using chimeric nanoparticle antigens containing epitopes from the circumspermatozoite protein (CSP) of the *Plasmodium falciparum* (*P. falciparum*) malaria parasite genetically fused either to HBcAg [59] (in Malarivax) or to HBsAg (in Mosquirix) [60]. This latter construct, presenting CSP residues 207–395 of *P. falciparum* NF54, is the key component of the RTS,S (Mosquirix) vaccine for which in mid-2015 the European Medicines Agency expressed a positive scientific opinion, following large-scale safety and efficacy data from phase III clinical trials [61–63] (Table 1). Although the latter is

| Platform | Antigen | Target | Expression system | Stage | Ref. |
|----------|---------|--------|------------------|-------|------|
| HBsAg    | HBsAg   | Hepatitis B virus | Yeast | Several licenses | [36,37] |
| HBcAg    | P. falciparum CSP 207–395 | Malaria | Yeast | Phase III | [53] |
| HBcAg    | P. falciparum CSP T and B-cell epitopes | Malaria | Bacteria | Phase I | [58] |
| HBcAg    | Glycoprotein F (fragment) | RSV | Bacteria + chemical conjugation | Preclinical | [67] |
| HBcAg    | Influenza matrix protein 2 | Influenza | Bacteria | Phase I | [78] |
| HEV      | HEV capsid polyepitope | Hepatitis E virus | HPV | Phase IV | [79] |
| HPV L1   | HPV L1 major capsid protein | HPV | Yeast | Several licenses | [26,27] |
| Hemagglutinin | HA | Influenza | Insect cells | Licensed | [82] |
| Full length HA/NA/NS1 | HA, NA, M1 | Influenza | Insect cells | Phase II | [78] |
| Bacteriophage Q1 | Nicotine hapten | Nicotine | Bacteria + chemical conjugation | Phase II | [63] |
| Bacteriophage Q1 | Aβ40 epitope | Alzheimer | Bacteria + chemical conjugation | Phase II | [64] |
| Bacteriophage Q1 | B1-15 | Type II diabetes mellitus | Bacteria + chemical conjugation | Phase I | [123] |
| Bacteriophage Q1 | Angiotensin II | Hypertension | Bacteria + chemical conjugation | Phase II | [124] |
| Bacteriophage Q1 | Peptide 207-233 of Melanin/MART-1 | Malignant melanoma | Bacteria + chemical conjugation | Phase II | [125] |
| Alfalfa mosaic virus | Peptides from rabies proteins G and N | Rabies | Plant | Phase I | [126] |
| NoV capsid protein | NoV capsid protein | Human norovirus | Insect cells | Phase I | [127] |
| NoV capsid protein | NoV capsid protein | Human norovirus | Plant | Phase I | [128] |
| Parvovirus B19 capsid proteins | Proteins VP1, VP2 | Human parvovirus | Insect cells | Phase I | [129] |

Abbreviations: HBsAg, hepatitis B surface antigen; HBcAg, hepatitis B core antigen; CSP, circumsporozoite; RSV, respiratory syncytial virus; HPV, human papillomavirus; HA, hemagglutinin; NA, neuraminidase; M1, matrix protein 1; NoV, norovirus.

Table 1
A table listing nanoparticle platforms of viral nature, with their composition, production method and stage of (pre)clinical development.

Hepatitis E virus (HEV) constitutes another successful example of the generation of recombinant VLPs with efficacy in preventing the progress of the infection. While insect cells have been used to prepare HEV particles of a truncated version of the HEV viral capsid protein that yielded an antigenicity similar to that of original HEV viral particles [71], a bacteria-derived HEV particle with a shorter polyepitodic subunit rendered up to 86.8% efficacy and is currently in phase IV clinical trials (Hecolin) [72,73].
The need for next-generation vaccines against influenza has been one of the biggest drivers of research into novel VLP antigens. For several decades, influenza vaccines have been successfully produced using embryonated chicken eggs [4]. Nevertheless, considerable efforts have been invested to devise alternative production methods for recombinant influenza antigens that might increase the vaccine manufacturing speed, yield, volume, purity and safety, and overcome the potential inability to provide sufficient vaccine doses in the event of future widespread epidemics or pandemics. In particular, several groups have explored influenza virus-like particles (VLPs): self-assemblies of the hemagglutinin (HA) and neuraminidase (NA) antigens on a lipid bilayer supported by the M1 matrix protein, generating non-infectious particles of approximately 100–150 nm diameter, thus resembling influenza virions [10,74]. Following progress in making recombinant self-assembling VLPs from Sf9 insect cells [75], influenza VLPs were shown to be promising immunogens [76]. This recombinant system enables tailored antigen expression levels, overcoming the issues of low abundance of NA or M1 in the traditional egg-based influenza vaccines. Using this system, a recombinant VLP designed to protect against the avian influenza A H7N9 strain was generated [77]. The latter induced protective immunity in ferrets [78] and showed positive phase I clinical results [79]. Moreover, several similar VLP vaccines have been tested in preclinical studies; for example, H7N9 VLPs were produced in mammalian 293T cells, and raised high titers of neutralizing antibodies in mice [80]. Further, mice were broadly protected by a vaccine cocktail of VLPs displaying H1, H3, H5 and H7 hemagglutinin antigens [81]. These data suggest that the influenza VLP approach may be applicable as a rapid response to potentially pandemic strains and, moreover, they can also be used to prepare seasonal quadrivalent influenza vaccines (QIV), for which clinical trials are ongoing.

Nevertheless, a novel approach for the prevention of influenza in individuals aged 18 and older has been achieved with the development of Flublok, the first recombinant influenza vaccine to have been licensed. This trivalent vaccine contains recombinant HA proteins of three strains of seasonal influenza virus [82] and its higher antigen load has been reported to improve immunogenicity and efficacy [83]. Produced in insect cells, these proteins adopt multimeric nanoparticulate structures of 20–40 nm in diameter as characterized by dynamic light scattering and electron microscopy.

While influenza is one of the most promising targets for recombinant VLP technology, other viral targets have proved more challenging, especially when several viral proteins are required for VLP assembly [34, 35]. Although the currently licensed rotavirus (RV) vaccines are very efficacious, improved RV vaccines are needed to provide greater protection in developing countries and to improve protection against mild gastroenteritis. To this end, several rotavirus VLPs have been tested in preclinical models. For example, double-layered RV VLPs (~60 nm diameter, obtained using insect cell expression) made of recombinant VP2 and VP6 proteins, the most abundant RV antigens, conferred partial protection in animals, but required adjuvant or priming with live-attenuated RV vaccine [84]. More recently, progress has been made using E. coli as a suitable low-cost scalable production system for VP2–VP6 rotavirus VLPs that elicited a strong antibody response and protection against RV-induced diarrhea in mice [85]. These RV studies suggest that such VLPs hold promise, but likely require additional optimization of composition, immunization route, and effective adjuvants to be efficacious in humans.

Attempts to make HIV vaccines have also included various different VLPs, mostly involving lipid-enveloped assemblies where the internal HIV Gag p24 provides support for exposure of trimers of Env, the crucial
HIV target antigen for neutralizing antibodies. A number of preclinical studies have shown the potential of this approach to efficiently induce humoral and cellular immune responses [86]. The initiation of future human clinical trials using emerging HIV VLP vaccine candidates should be facilitated by the clinical development experience (manufacturing, safety, etc.) accrued in the generation of influenza and rotavirus vaccines described above.

Human norovirus (NoV) causes endemic viral diarrheal disease and may cause up to half of all gastroenteritis outbreaks worldwide, and therefore is gaining increasing attention as another pathogen causing a globally significant healthcare burden [87,88]. Candidate NoV VLP vaccines have been developed using the recombinant VP1 protein (the major NoV antigen) which self-assembles into nanoparticles (diameter ~30 nm) closely resembling the native virion [89]. A number of clinical trials have been performed (Table 1) and showed that NoV VLP vaccines are well tolerated and can induce rapid, robust immune response in adults [88]. However, in the clinical trials reported to date, results demonstrate modest protection from infection and disease and some prevention of severe gastroenteritis in healthy subjects, while efficacy data for the key ‘at risk’ groups have not yet emerged [87]. While the VLP platform appears promising, a key question for NoV vaccine development is the breadth of protection against multiple variant genotype strains, potentially resolvable using multivalent NoV VLP cocktails.

The viral examples described above clearly demonstrate the success, and future promise, of using highly purified non-enveloped viral capsid proteins as plain or chimeric antigen nanoparticles. However, enveloped VLPs, due to the inclusion of a lipid bilayer in addition to the structural protein antigens, represent a more complex challenge that is now being partly overcome via breakthroughs in mammalian and insect cell expression technologies. Unlike the simpler non-enveloped viral protein nanoparticles, enveloped VLPs have more inherent safety issues due to potential contaminations from the expression system used, and may be more challenging to formulate with long-term stability profiles. Nevertheless, several enveloped VLP candidates are now in clinical trials.

2.2. Bacterial protein platforms

In addition to viral nanoparticles or VLPs, there are many other naturally occurring self-assembling protein nanoparticles that have been identified from a wide variety of sources [9]. For example, almost all living organisms produce ferritin, a protein whose main function is intracellular iron storage. Ferritin is made of 24 subunits, each composed of a four-alpha-helix bundle, that self-assemble in a quaternary structure with octahedral symmetry (Fig. 3).

Several high-resolution structures of ferritin have been determined, confirming that Helicobacter pylori ferritin is made of 24 identical protomers [90], whereas in animals, there are ferritin light and heavy chains that can assemble alone or combine with different ratios into particles of 24 subunits [91,92].

Ferritin self-assembles into nanoparticles with robust thermal and chemical stability. Hence, the ferritin nanoparticle is potentially well-suited to carry and expose immunogens. Moreover, since ferritin is composed of eight units each with three-fold axis symmetry, it is a convenient scaffold for the presentation of trimeric antigens. Indeed, Nabel and co-workers reported an elegant structure-based design strategy to generate ferritin nanoparticles genetically engineered to present a multivalent array of the flu virus hemagglutinin (HA) with its native trimeric conformation intact. HA is the key antigenic component of flu vaccines, and immunization of mice with these HA-ferritin nanoparticles yielded a very promising outcome: compared to a current commercial vaccine, the animals responded with a more potent immune response, as illustrated by the notably higher number of neutralizing antibodies, enhanced breadth of coverage against unmatched H1N1 viruses and increased generation of neutralizing Abs against both H1N1 highly conserved, yet independent, flu epitopes [93]. This work was one of the first clear examples of how the structurally optimized presentation of ordered arrays of a well-folded immunogen can induce stronger protection. In more recent work aiming towards a universal flu vaccine by providing broad coverage of protection against different subtypes of the flu virus, Yassine et al. reported a refined structure-based generation of a ferritin-based nanoparticle that displayed only the...
stem region of the H1 HA glycoprotein, yet was capable of evoking broadly cross-reactive antibodies that, in contrast to plain nanoparticles, protected mice and ferrets against lethal doses of heterosubtypic H5N1 virus [94].

Another similar study was also reported by the Nabel team, wherein the conserved receptor-binding domain (a site of vulnerability) of the gp350 antigen from Epstein–Barr virus was presented in a structurally optimized orientation on nanoparticles of ferritin (24 subunits) or encapsulin (60 subunits). In preclinical studies, the chimeric nanoparticle–gp350 antigens elicited 10- to 100-fold more potent virus-neutralizing antibody titers than the soluble gp350 antigens alone [95]. Importantly, in addition to their immuno-focusing ability to generate high-quality antibody responses, the recombinant nature of these nanoparticle antigens has the benefit of high purity, safety, and tolerability, further strengthening the appropriateness of this vaccination strategy (Table 2).

Also, very recent is the work by He et al., describing in silico studies to optimize molecular scaffolds for epitope presentation and leading to the generation of recombinant ferritin nanoparticles displaying epitope-scaffolds harboring E1 or E2 epitopes from hepatitis C virus, promising candidates for preclinical studies in the quest for an HCV vaccine [96]. This recent example applied to HCV builds on the epitope-scaffold rational design strategy that emerged in previous attempts to graft HIV epitopes onto heterologous protein scaffolds [97], and effectively combines this approach with the multivalent nanoparticle format.

Ferritin has also been used as antigen support in the search for potent and safe vaccine tools against HIV [98], which despite its identification more than 30 years ago remains as one of the most devastating pathogens affecting the human population. In order to circumvent the fact that Abs others than the so-called broadly neutralizing antibodies (bNAb) might occlude highly vulnerable HIV sites, Kwong and co-workers grafted a series of these HIV target motifs into different protein templates and the resultant chimeras were named ‘supersite transplants’. Transplants bearing a glycopeptide from the variable region 3 on gp120 were recognized by neutralizing antibodies from three different donors, and binding was enhanced by presentation of the transplants on ferritin nanoparticles.

Lumazine synthase (LS) represents another example of the inclusion of a bacterial particulate base for the optimization of vaccine candidates, as reported recently by Jardine et al. in their attempts to enhance the immunoreactivity of recombinant gp120 against HIV infection [99]. As mentioned before, HIV represents a major health problem worldwide. With 35 million people carrying the virus worldwide and a yearly morbidity of 1.7 million people (AVERT, http://www.avert.org/worldwide-hiv-aids-statistics.htm), the lack of a vaccine is an enormous unmet medical need. A key challenge in designing an anti-HIV vaccine is the high mutagenic capability of the virus and the unfeasibility of administering attenuated or killed virus because of safety issues. An additional hurdle is the negligible recognition potential of germline precursors of bNAb, such as VRC01, against the wild-type gp120, the major immunogenic component of the HIV virus envelope. One way to overcome this obstacle was recently reported by Schief and co-workers [99], whoBoosted the affinity of the germline antibodies for the viral gp120 glycoprotein by displaying multiple copies of an engineered form of the antigen on a lumazine synthase (LS) nanoparticle.

LS, which is responsible for the penultimate catalytic step in the bio-synthesis of riboflavin, is an enzyme present in a broad variety of organisms, including archaea, bacteria, fungi, plants, and eubacteria [100]. The LS monomer is 150 amino acids long, and consists of beta-sheets along with tandem alpha-helices flanking its sides. A number of different quaternary structures have been reported for LS, illustrating its morphological versatility: from homopentamers up to symmetrical assemblies of 12 pentamers forming capsids of 150 Å diameter. Even LS cages of more than 100 subunits have been described [101].

Using LS from the thermophilic bacterium *Aquific aeolicus* as a nanoparticle platform for epitope display, Jardine et al. succeeded in increasing the potency of the immune response and breadth of coverage against HIV. The envelope (Env) glycoprotein is the only HIV surface protein targeted by neutralizing antibodies; it is made of three gp160 precursors that trimerize and are each then cleaved into gp120 and gp41 subunits. Jardine et al. engineered LS to display an optimized sub-component (termed, eOD-GT6) of the wild-type gp120 antigen from the Env trimer [99]. This approach overcame the issue that germline precursors of VRC01 bNAb show undetectable affinity for wild-type Env. With additional structural stabilization of the trimer provided by an N-terminal coiled-coil GCN4 domain, the eOD-GT6 immunogen was fused to the C-terminus of the LS gene construct. The resulting recombinant nanoparticle antigens were efficiently obtained from mammalian cells, in stable and homogeneous self-assemblies of 60 LS monomers each presenting a glycosylated eOD-GT6. In contrast with the monomeric eOD-GT6 that did not stimulate B-cell activation, the LS-eOD-GT6 nanoparticles remarkably activated both germine and mature B cells. In accordance with related studies discussed above, Jardine et al. also hypothesize that the ability of the nanoparticles to induce cross-linking with the B-cell receptors was important to promote a successful immune response.

### 2.3. Micellar nanoparticles

A method to obtain protein micelles from full-length amphiphilic membrane proteins was developed and used to prepare viral surface proteins as water-soluble particles with a hydrophobic interior and a polar exterior, of relatively homogeneous size: approximately 20–30 nm diameter, depending on the protein [102]. Therein, Simons et al. predicted several possible applications of the approach, including the opportunity to make virus glycoprotein micelle vaccines. Indeed, a similar approach has been adapted for the preparation of protein nanoparticles comprised of amphiphilic antigens, where the protein micelles are prepared by extraction with non-ionic detergents from Sf9 insect cells expressing the recombinant antigen. In a compelling example, a slightly genetically modified full-length form of the RSV fusion (F) surface glycoprotein was extracted and purified from insect cell membranes and used to create protein nanoparticle micelles of ~40 nm diameter, where the trimeric F protein assembled into rosettes exposing conformational epitopes similar to those of the post-fusion F conformation and able to raise neutralizing Abs [103]. In very recent clinical trials, these RSV F antigen nanoparticles appeared safe, promoted immunogenicity, and reduced RSV infections [104], raising high expectations for a nanoparticle vaccine against RSV.

**Table 2**

| Platform        | Antigen            | Target                          | Expression system | Stage       | Ref. |
|-----------------|--------------------|---------------------------------|-------------------|-------------|-----|
| Ferritin        | GP350 CR2-binding  | Epstein–Barr virus              | Mammalian cells   | Preclinical | [94]|
| Ferritin        | E1 / E2 envelope   | Hepatitis C virus               | Mammalian cells   | Preclinical | [95]|
| Ferritin        | Variable region 3  | HIV                             | Mammalian cells   | Preclinical | [96]|
| Ferritin        | HA                 | Influenza                       | Mammalian cells   | Preclinical | [97]|
| Encapsulin      | GP350 CR2-binding  | Epstein–Barr virus              | Mammalian cells   | Preclinical | [98]|
| Lumazine Synthase| Engineered gp120   | HIV                             | Mammalian cells   | Preclinical | [99]|

Abbreviations: HIV, human immunodeficiency virus; HA, hemagglutinin.
The micellar nanoparticle approach has also been exploited in the search for vaccines against the Coronavirus virus (CoV) family, which represents an important group of emerging human pathogens, as witnessed in the severe acute respiratory syndrome SARS-CoV and Middle East respiratory syndrome MERS-CoV outbreaks of 2003 and 2012, respectively. Recombinant full-length forms of the major immunodominant CoV antigen—the amphiphilic spike glycoproteins—both from SARS-CoV and MERS-CoV were successfully obtained via non-ionic detergent-extraction from SF9 cells. The purified spike proteins assembled into nanoparticles of ~25 nm diameter that, in adjuvanted formulations tested in mice, were capable of raising high-titer neutralizing antibody responses against the homologous virus [105]. These preclinical examples suggest that this protein nanoparticle approach may be suitable for rapid production of relatively simple but effective vaccines in response to emerging pathogens (Table 3).

2.4. New protein platforms

Proposals to perform molecular manipulations that, by exploiting chemical forces in a repetitious fashion, could lead to the production of interesting materials that date back at least to the 1960s [14,15]. Indeed, in addition to the naturally occurring self-assembling proteins described above, several groups have explored ways to design and produce nanoparticle materials based on non-native polypeptides. For example, Burkhard and co-workers produced chimeric polypeptides capable of self-assembling into regular polyhedral nanoparticles [106]. The polypeptide consisted of an N-terminal pentamer-forming subunit derived from the cartilage oligomeric matrix protein (COMP), followed by a de novo-designed trimeric subunit domain. Both subunits present oligomeric coiled-coil conformations and importantly, the resultant synthetic molecule was shown to refold and self-assemble into nanoparticles with polyhedral symmetry. Alternative oligomerization motifs such as the trimeric foldon domain from fibrinogen have also been used in such designs [107]. The assembly of such nanoparticles gives rise to a multivalent molecular architecture that allows diverse immunogenic epitopes to be repeatedly displayed on the surface of the nanoparticles in a strictly arranged manner, a strategy that appears to be broadly applicable.

Indeed, using the polypeptide approach, the Burkhard team fused the C-terminal heptad repeat (HRC) region of the SARS-CoV spike protein in its pre-fusogenic state in frame with the nanoparticle scaffold [108]. This strategy allowed conservation of the trimeric coiled-coil conformation of the spike epitope. Immunization of mice with these SARS-nanoparticles successfully elicited neutralizing antibodies specific for the trimeric coiled-coil epitope of the pre-fusogenic HRC. Additional applications of this system targeted an HIV vaccine, by using a nanoparticle made of two covalently linked coiled-coil domains designed to incorporate the membrane proximal external region (MPER) of HIV-1 gp41 [109]. However, while high MPER-specific titers were raised by this nanoparticle, none of the sera displayed detectable neutralizing activity against HIV-1. More promisingly, similarly designed polypeptide nanoparticles displaying multiple copies of a rodent malaria epitope from the circumsporozoite protein of Plasmodium berghei elicited a long-lasting immune response [110]. Collectively, this preclinical research suggests that the self-assembling protein nanoparticle (SAPN) approach can generate safe non-native polypeptide antigens approximating the size and multivalent scenario of a virus and thus facilitate the recognition of the antigen by immune receptors.

Early in the 21st century, Yeates and co-workers developed the nanohedra protein-design method, which was subsequently extended by Noble and co-workers [111,112]. The Yeates team rationally designed genetic fusions of the trimeric bromoperoxidase and the dimeric M1 matrix protein of influenza virus, such that the combination of the two naturally oligomeric proteins generated self-assembling nanostructures, including a 15-nm-wide molecular cage and a 4-nm-wide filamentous superstructure [111,112]. Later, a well-ordered tetrahedral cage with 12 subunits was designed and its crystal structure was determined and revealed to closely match the intended design, validating this approach [113]. The Noble team used proteins with higher symmetry, allowing design of fusions with two or more connections, generating regular molecular arrays that formed protein lattices, but not closed nanohedral particles [114]. Several subsequent in silico and crystallographic studies have further developed nanostructure design strategies, including the generation of particles over 22 nm in diameter [115]. Therefore, with the development of these more powerful computational approaches for the ab initio design of new protein-protein interfaces with defined symmetry, geometry, and complementary packing arrangements, and the increasing number of protein structures in the PDB, it is speculated that additional achievements in the field of self-assembling protein design will be possible [96,115–122]. It will be interesting to see if such scaffolds can be fully exploited to display antigenic epitopes suitable for full development into clinically efficacious vaccines.

3. Conclusions

Despite many successes in the field of vaccinology, new breakthroughs are still needed to protect humans from several important life-threatening diseases. Here, we have reviewed how a variety of non-infectious biological nanoparticles can offer solutions. For example, some plain nanoparticles (e.g. HBsAg or the HPV L1 protein) are simple molecular self-assemblies that are safe and efficacious vaccine antigens licensed for human use. Or, more complex chimeric nanoparticles can be platforms on which pathogen-derived immunogenic motifs can be presented to the host immune system. These biological scaffolds range from synthetic polypeptides to native macromolecules such as ferritin, lumazine synthase or VLP-forming antigens or lipid-enveloped VLPs. For some chimeric nanoparticles, there is evidence that the immunogenicity of the platform carrier itself is negligible or low compared to that of the mounted immunogen being presented [93]. Because these nanoparticles display an ordered matrix of immunogens, they enable more

---

**Table 3**

A table listing nanoparticle platforms of diverse nature, with their composition, production method, and stage of (pre)clinical development.

| Platform                  | Antigen                      | Target                          | Expression system | Stage      | Ref.       |
|---------------------------|------------------------------|---------------------------------|-------------------|------------|-----------|
| Micellar protein          | Glycoprotein F               | RSV                             | Insect cells      | Phase II   | [103]     |
| Micellar protein          | Spike glycoprotein S         | SARS and MERS coronavirus       | Insect cells      | Preclinical| [104]     |
| Virosome                  | Her-2 peptides of Her-2/neu  | Breast cancer                    | Cell free         | Phase I    | [130]     |
| Virosome                  | Asparyl proteinase-2         | Candida albicans                 | Cell free         | Phase I    | [131]     |
| Virosome                  | P1 and recombinant gp41      | HIV                             | Cell free         | Phase I    | [132]     |
| Ty p1                     | p17/p24                      | HIV                             | Yeast             | Phase II   | [134]     |
| Synthetic polypeptide     | Heptad repeat of CoV spike protein (pre-fusogenic state) | Bacteria | Preclinical | [107]     |
| Synthetic polypeptide     | Membrane proximal gp41      | HIV                             | Bacteria          | Preclinical| [108]     |
| Synthetic polypeptide     | Plasmodium berghei CSP B-cell epitope | Malaria | Bacteria | Preclinical| [109]     |

Abbreviations: CSP, circumsporozoite; RSV, respiratory syncytial virus; HA, hemagglutinin; NA, neuraminidase; SARS, severe acute respiratory syndrome; MERS, Middle East respiratory syndrome; HIV, human immunodeficiency virus.
fruitful engagements with the B-cell receptors than single recombinant immunogens can establish. Several animal models and clinical studies have been reported that exemplify the high efficiency of these nanostructures in eliciting potent and long-lasting immunity. Following successful clinical studies, a recombinant nanoparticle-based vaccine against malaria is emerging, and two vaccines are already available to prevent HIV-related diseases.

Recent preclinical studies have demonstrated how computational and structural biology can be combined for the rational design of well-oriented arrays of the most protective epitopes of a pathogen, in a manner suitable to raise the most desired immune responses. Further, the computational ab initio design of self-assembling molecules is becoming ever more possible, thus enriching our molecular repertoire of nanoparticle scaffolds. Consequently, the design of plain or chimeric nanoparticle antigens, and the ability to manufacture these recombinantly in prokaryotic or eukaryotic systems, to make safe and effective immunogens, is becoming a reality. We have shown that vaccination clinical trials against a broad range of diseases are ongoing. While there are established examples of successful vaccines against diseases of viral and parasitic origin (hepatitis B, HPV, malaria), the next decade may consolidate the use of multivalent nanoparticles as a therapeutic tool for the future against infectious diseases of other origins (bacterial, fungal) but also against cancers and other disorders such as hypertension, asthma, or addictions (e.g. smoking). These amazingly versatile tools may also get us closer to universal vaccines against highly variable pathogen sequences via genetically engineered filamentous phage, J Biol Chem 1988; 263:4318–22.

Burls NR, Sabil HR, White NS, Pardon JF, Timminns PA, Richardson SM, et al. Symmetry, flexibility and permeability in the structure of yeast retrotransposon virus-like particles. EMBO J 1992;11:153–64.

Clarke BE, Newton SE, Carroll AR, Francis MJ, Appleyard G, Syred AD, et al. Improved immunogenicity of a peptide epitope after fusion to hepatitis B core protein. Nature 1987;330:381–4.

Delpeyroux F, Chesnoux N, Lim A, Malpieve J, Blondel B, Crainick R, et al. A poliovirus neutralization epitope expressed on hybrid hepatitis B surface antigen particles. Science 1986;233:472–8.

Belyaev AS, Roy P. Presentation of hepatitis B virus preS2 epitope on bluetongue virus core-like particles. Virology 1992;190:840–4.

Brown CS, Welling-Wester S, Feijelb M, Van Lent JW, Spann WA, Chimeric parvovirus B19 capsids for the presentation of foreign epitopes. Virology 1994;198: 477–88.

Hwang DJ, Roberts IM, Wilson TM. Expression of tobacco mosaic virus coat protein and assembly of pseudovirus particles in Escherichia coli. Proc Natl Acad Sci U S A 1994;91:9067–71.

Yeates TO, Jacobson DM, Martin A, Wychowski C, Giraud M, Filman DJ, et al. Three-dimensional structure of a mouse-adapted type 2/J type 1 poliovirus chimera. EMBO J 1991;10:2331–41.

London SD, Schmaljohn AL, Dalympie JL, Rice CM. Infectious envelope RNA virus antigens in chimeras. Proc Natl Acad Sci U S A 1992;89:207–11.

Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Lodolter et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007;356:1928–43.

Paavonen J, Jenkins D, Bosch FX, Naud P, Salmeron J, Wheeler CM, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007:369:2161–70.

Mato M, Carfi A, Bottoney MJ. Protein Crystallography in Vaccine Research and Development. Int J Mol Sci 2015;16:13106–40.

Dormitzer PR, Grandi G, Rappuoli R. Vaccinology strategies starts to deliver. Nat Microbiol 2012;10:807–11.

Irvin DJ, Hanson MC, Rahkia K, Toklatian T. Synthetic Nanoparticles for Vaccines and Immunotherapy. Chem Rev 2015;115:19:11190–46.

Smith JD, Morton LD, Uley B. Nanoparticles as synthetic vaccines. Curr Opin Biotechnol 2015;34:217–24.

Singh M, Chakravani A, O’Hagan D. Nanoparticles and microparticles as vaccine-delivery systems. Expert Rev Vaccines 2007:6:797–808.

Fernandes F, Teixeira AP, Carinhas N, Carrondo MJ, Alves PM. Insect cells as a pro-ductive platform for the production of large quantities of recombinant viral vaccines. Int J Mol Sci 2015;16:13106–9.

Valenzuela P, Medina A, Rutter WA, Ammerer G, Hall BD. Synthesis and assembly of hepatitis B virus surface antigen particles in yeast. Nature 1982:298:347–50.

McAuleer WJ, Buynak EB, Maigetter RZ, Wampler DE, Miller WJ, Hillerman MR. Immunogenicity and protective efficacy of hepatitis B vaccines. J Virol 1994;68:53–75.

Kang SM, Pushkio P, Bright RA, Smith G, Compaas RW. Influenza virus-like particles as pandemic vaccines. Curr Top Microbiol Immunol 2005:277:209–89.

Ogwumike EO, Muralian N, Cui Z. Nanoparticles as immune adjuvants: correlating particle sizes and the resultant immune responses. Expert Rev Vaccines 2010:9:1095–107.

Castañón JR, Carrascosa JL. The basic architecture of viruses. Subcell Biochem 2013; 68:53–75.

Goodsell DS, Olson AJ. Structural symmetry and protein function. Annu Rev Biophys Biomol Struct 2000:29:105–53.

Foycett RP. There’s plenty of room at the bottom. Eng Sci 1960:22–36.

Rajagopal K, Schneider JP. Self-assembling peptides and proteins for nanotechnological applications. Curr Opin Struct Biol 2004;14:480–6.

Drexler KE. Molecular engineering: An approach to the development of general ca-pacity for molecular manipulation. Proc Natl Acad Sci U S A 1981;78:5275–8.

King NP, Lai YT. Practical approaches to designing novel protein assemblies. Curr Opin Struct Biol 2013;23:632–8.

de la Cruz YF, Lal AA, McCutchan TF. Immunogenicity and epitope mapping of for-eign sequences via genetically engineered filamentous phage. J Biol Chem 1988; 263:4318–22.

Blyska B, Bauer D, Hild T. The basic architecture of viruses. Subcell Biochem 2013; 68:53–75.
Smith GE, Flyer DC, Raghunandan R, Liu Y, Wei Z, Wu Y, et al. Development of an alphavirus-based vaccine for hepatitis C virus. J Virol 2015;89:1428–38.

Lowry DR, Solomon D, Hildenstein A, Schiller JT, Schiffman M. Human papillomavirus infection and the primary and secondary prevention of cervical cancer. Cancer 2008;113:1980–93.

Sahara M, Parker M, Aha P, Cosco C, Gibbons E, Parsons S, et al. Assembly of double-shelled rotavirus-like particles by simultaneous expression of recombinant VP6 and VP7 proteins. Virology 1991;189:694–7.

Uraga T, Ferguson M, Minor PD, Rajamani L, Uchida T, et al. Expression and purification of chimeric virus-like particles from the Sindbis virus E1 glycoprotein and recombinant hepatitis C virus core protein. J Virol 1998;72:6513–26.

Grgacic EV, Anderson DA. Virus-like particles: passport to immune recognition. J Gen Virol 2009;90:2255–66.

Correia BE, Bates JT, Loomis RJ, Baneyx G, Carrico C, Jardine JG, et al. Proof of concept for epitope-focused vaccine design. J Mol Biol 2006;362:753–62.

Cardone G, Moyer AL, Cheng N, Thompson CD, Dvoretzky I, Lowy DR, et al. Maturation of empty virus-like particles of hepatitis E virus. J Virol 1997;71:2707–13.

Zhang J, Zhang XF, Huang SJ, Wu T, Hu YM, Wang ZZ, et al. Long-term efficacy of a hepatitis E vaccine. N Engl J Med 2015;372:914–22.

Zhu FC, Zhang J, Zhang XY, Zhou C, Wang ZZ, Huang SJ, et al. Safety and efficacy of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial. Lancet 2010;376:895–902.

Haynes JR. Influenza virus-like particle vaccines. Expert Rev Vaccines 2009;8:435–45.

Latham T, Galarza JM. Formation of wild-type and chimeric influenza virus-like particles following simultaneous expression of only four structural proteins. J Virol 2007;81:6794–7.

Galarza JM, Latham T, Cupo A. Virus-like particle (VLP) vaccine conferred complete protection against a lethal influenza virus challenge. Viral Immunol 2005;18:244–51.

Smith GE, Flyer DC, Raghunandan R, Liu Y, Wei Z, Wu Y, et al. Development of influenza H7N9 virus-like particle (VLP) vaccine: homologous A/H1N1/2013 (H7N9) protection and heterologous A/hen/ijssel/cp/2012 (H7N9) cross-protection in vaccinated mice challenged with H7N9 virus. Vaccine 2013;31:4305–13.

Liu YM, Masseur MJ, Menichini MB, Sun X, Beiler JA, Maines TR, et al. Recombinant virus-like particles elicit protective immunity against avian influenza A(H7N9) virus infection in ferrets. Vaccine 2015;33:2152–8.

Fries LF, Smith GE, Clemm A. A recombinant virus-like particle influenza A (H7N9) vaccine: phase II dose-escalation study. J Virol 2015;89:6944–54.

Zhang L, Lu J, Chen Y, Shi F, Yu H, Huang C, et al. Characterization of Humoral Responses Induced by an H7N9 Influenza Virus-Like Particle Vaccine in BALB/c Mice. Viruses 2015;7:4963–84.

Schwarzman LM, Cathcart AL, Pujanauskas ML, Qi L, Kash JC, Taubenberger JK. An Influenza Virus-Like Particle Vaccine Broadly Protects Mice from Multiple Subtypes of Influenza A Virus. MBio 2015;6:e01044.

Lashencho E, Rhodes DL, Felberbaum RM, McPherson C, Rinnering JA, Post P, et al. Pan-Flu: Influenza vaccine characterization of A/California/07/2009 (H1N1) recombinant hemagglutinin protein and insights into H1N1 antigen stability. BMC Biotechnol 2012;12:77.

Cox MM, Izkisson R, Post P, Dunkle L. Safety, efficacy, and immunogenicity of Flublok in the prevention of seasonal influenza in adults. Ther Adv Vaccines 2015;3:97–108.

Azevedo MP, Vlasova AN, Safi J. Human rotavirus virus-like particle vaccines evaluated in a neonatal gnotobiotic pig model of human rotavirus disease. Expert Rev Vaccines 2013;12:169–81.

Li T, Lin H, Zhang YJ, Wu M, Deng C, Che Y, et al. Improved characteristics and protective efficacy in an animal model of eG-derived recombinant double-layered rotavirus virus-like particles. Vaccine 2014;32:1921–31.

Buonaguro L, Tagliamonte M, Visciano ML, Tornesello ML, Buonaguro FM, Development in virus-like particle-based vaccines for HIV. Expert Rev Vaccines 2013;12:119–27.

Shahab NA, Lopman BA, Pararaj SE, Hall AJ. Progress toward norovirus vaccines: considerations for further development and implementation in potential target populations. Expert Rev Vaccines 2015;14:1241–53.

Richardson C, Bargatze RF, Goodwin R, Mendelmann PM. Norovirus virus-like particle virosomes for the prevention of acute gastroenteritis. Expert Rev Vaccines 2013;12:155–67.

Jiang X, Wang M, Graham DV, Estes MK Expression, self-assembly, and antigenicity of the Norwalk virus capsid protein. J Virol 1992;66:6527–32.

Cho KJ, Shin HJ, Lee BH, Kim JK, Park SS, Lee Y, et al. The crystal structure of ferritin from Helicobacter pylori reveals unusual conformational changes for iron uptake. J Mol Biol 2009;390:83–98.

Graiter T, Langlois d’Estaintot B, Gallois B, Chevalier JM, Precigoux C, Santambrogio P, et al. Structure of the active sites of mouse L-chain ferritin at 1.2 Å resolution. J Biol Inorg Chem 2003;8:105–11.

Lawson DM, Artesikjian PJ, Yewdall SJ, Smith JM, Livingstone JC, Trevitt A, et al. Solving the structure of human H ferritin by genetically engineering intermolecular crystal contacts. Nature 1991;349:541–4.

Kaneko M, Wei CJ, Yasmine HM, McMaster PM, Boyington JC, Whittle JR, et al. Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. Nature 2013;495(7456):102–6.

Yasmine HM, Boyington JC, McMaster PM, Wei CJ, Kaneko M, Wong WP, et al. Hemagglutinin-tagged nanoparticles generate heterotypic subtype specificity. Nat Med 2015;21(9):1065–70.

Kaneko M, Bu W, Joyce MG, Meng W, Whittle JR, Baxa U, et al. Rational Design of an Influenza Virus Vaccine Targeting the Receptor-Binding Site. Cell 2015;162(5):1090–100.

He L, Cheng Y, Kong L, Azadina P, Giang E, Kim J, et al. Applying rational epitope vaccine design for hepatitis C virus with meta-server and multivalent scaffolding. J Med Chem 2015;5:12595–612.

Burton DR. Scaffolding to build a rational vaccine design strategy. Proc Natl Acad Sci U S A 2010;107:17859–60.

Zhou T, Zhu J, Yang J, Gorman J, Ofek G, Srivatsan S, et al. Transplanting supersites into the human papillomavirus 16 capsid. MBio 2014;5:e01104.

Jardine J, Julian JP, Menis S, Ota T, Kalyuzhny O, McGuire A, et al. Rational HIV immunogen design to target specific germline B cell receptors. Science 2013;340:611–6.

Weber SA, Flavins and Flavoproteins. Methods and Protocols, Series: Methods in Molecular Biology 2014, 1146.

Zhang X, Konarev PV, Potokhov MV, Svergun DI, Xi L, Cheng RH, et al. Multiple assem- bling in the states of luminescent states of a model relating catenoid and functional morphology. J Mol Biol 2006;362:753–70.

Simons K, Helenius A, Leonard K, Sarvas M, Gething MJ, Formation of protein mi- celles from amphiphilic membrane proteins. Proc Natl Acad Sci U S A 1978;75:3668–71.

Smith G, Raghunandan R, Wu Y, Liu Y, Masseur M, Nathan M, et al. Respiratory synca- vira virus fusion glycoprotein expressed in insect cells form protein nanoparticles that induce protective immunity in cotton rats. PLoS One 2012;7:e58582.

Glennon CM, Fries LF, Thomas PS, Smith G, Espemagen E, Lu H, et al. A randomized, blinded, controlled, dose-ranging study of a respiratory viral recombinant fusion (f) nanoparticle vaccine in healthy women of childbearing age. J Infect Dis 2015;211:530–6.

Glennon CM, Liu YY, Mu H, Taylor JR, Masseur M, Flyer DC, et al. Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice. Vaccine 2014;32:6169–74.

Raman S, Machaidez G, Lustig A, Aebi U, Burkhard P. Structure-based design of peptides that self-assemble into regular polyhedral nanoparticles. Nanomedicine 2006;2:95–102.
King NP, Bale JB, Shefler S, Cooper S, Khatib F, Treuille A, Barbero J, Lee J, Beenen M, et al. Predicting protein nanoparticles using simple protein oligomerization domains. Open Nanomedicine J 2009;2:15–26.

Pimentel TA, Yan J, Jeffers SA, Holmes Kv, Hodges RS, Burkhard P. Peptide nanoparticles as novel immunogens: design and analysis of a prototypic severe acute respiratory syndrome vaccine. Chem Biol Drug Des 2009;73:53–61.

Walheme N, Pfeiffer T, Ambiel I, Yang Y, Keppler OT, Bosch V, et al. Conformation-specific display of 4E10 and 2F5 epitopes on self-assembling protein nanoparticles as a potential HIV vaccine. Chem Biol Drug Des 2012;80:349–57.

Kaba SA, Brando C, Guo Q, Mittelhozer C, Raman S, Tropel D, et al. A nonadjuvanted polypeptide nanoparticle vaccine confers long-lasting protection against rodent malaria. J Immunol 2009;183:7268–77.

Yeates TO, Padilla JE. Designing supramolecular protein assemblies. Curr Opin Struct Biol 2002;12:464–70.

Watanabe K, Kuhlman B, Baker D. Native protein sequences are close to optimal for their structures. Proc Natl Acad Sci U S A 2001;98:2217–21.

Lai YT, Cascio D, Yeates TO. Structure of a 16-nm cage designed by using protein oligomers. Science 2012;336:1129.

Sinclair JC, Davies KM, Venien-Bryan C, Noble ME. Generation of protein lattices by fusing proteins with matching rotational symmetry. Nat Nanotechnol 2011;6:558–62.

Lai YT, Reading E, Hura GL, Tsai KL, Laganowsky A, Asturias FJ, et al. Structure of a designed protein cage that self-assembles into a highly porous cube. Nat Chem 2011;3:576–80.

Yeates TO, Padilla JE. Nanohedra: using symmetry to design self-assembling protein cages, layers, crystals, and filaments. Proc Natl Acad Sci U S A 2001;98:2217–21.

DiMaio F, Leaver-Fay A, Bradley P, Baker D, Andre I. Modeling symmetric macromolecular structures in Rosetta3. PLoS One 2011;6:e20450.

Kaba SA, Brando C, Guo Q, Mittelhozer C, Raman S, Tropel D, et al. A nonadjuvanted polypeptide nanoparticle vaccine confers long-lasting protection against rodent malaria. J Immunol 2009;183:7268–77.

Yeates TO, Padilla JE. Designing supramolecular protein assemblies. Curr Opin Struct Biol 2002;12:464–70.

Padilla JE, Colovos C, Yeates TO. Nanohedra: using symmetry to design self-assembling protein cages, layers, crystals, and filaments. Proc Natl Acad Sci U S A 2001;98:2217–21.

Lai YT, Cascio D, Yeates TO. Structure of a 16-nm cage designed by using protein oligomers. Science 2012;336:1129.

Sinclair JC, Davies KM, Venien-Bryan C, Noble ME. Generation of protein lattices by fusing proteins with matching rotational symmetry. Nat Nanotechnol 2011;6:558–62.

Lai YT, Reading E, Hura GL, Tsai KL, Laganowsky A, Asturias FJ, et al. Structure of a designed protein cage that self-assembles into a highly porous cube. Nat Chem 2011;3:576–80.

Yeates TO, Padilla JE. Nanobiotechnology: protein arrays made to order. Nat Nanotechnol 2011;6:541–2.

King NP, Shefler W, Sawaya MR, Vollmar BS, Sumida JP, Andre I, et al. Computational design of self-assembling protein nanomaterials with atomic level accuracy. Science 2012;336:1711–4.

DiMaio F, Leaver-Fay A, Bradley P, Baker D, Andre I. Modeling symmetric macromolecular structures in Rosetta3. PLoS One 2011;6:e20450.

Kuhlman B, Baker D. Native protein sequences are close to optimal for their structures. Proc Natl Acad Sci U S A 2000;97:10383–8.

Cooper S, Khatib F, Treuille A, Barbero J, Lee J, Beeram M, et al. Predicting protein structures with a multiplayer online game. Nature 2010;466:756–60.

King NP, Bale JB, Shefler W, McNamara DE, Gonen S, Gonen T, et al. Accurate design of co-assembling multi-component protein nanomaterials. Nature 2014;510:103–8.

Leaver-Fay A, Tyka M, Lewis SM, Thompson J, Jacak R, et al. ROSETTA3: an object-oriented software suite for the simulation and design of macromolecules. Methods Enzymol 2011;487:545–74.

Spohn C, Schori C, Keller I, Sladko K, Sina C, Guler R, et al. Preclinical efficacy and safety of an anti-IL-1beta vaccine for the treatment of type 2 diabetes. Mol Ther Methods Clin Dev 2014;1:14048.

Phisitkul S, CYT-006-AngQb, a vaccine against angiotensin II for the potential treatment of hypertension. Curr Opin Investig Drugs 2009;10:269–75.

Goldinger SM, Dummer R, Baumgaertner P, Mihic-Probst D, Schwarz K, Hammann-Haenni A, et al. Nano-particle vaccination combined with TLR-7- and -9 ligands triggers memory and effector CD8 (+) T-cell responses in melanoma patients. Eur J Immunol 2012;42:3049–61.

Yusibov V, Hooper DC, Spitsin SV, Fleysh N, Kean RB, Mikheeva T, et al. Expression in plants and immunogenicity of plant virus-based experimental rabies vaccine. Vaccine 2002;20:3155–64.

Atmar RL, Bernstein DH, Harro CD, Al-Ibrahim MS, Chen WH, Ferreira J, et al. Norovirus vaccine against experimental human Norwalk Virus illness. N Engl J Med 2011;365:2178–87.

Mason HS, Ball JM, Shi J, Jiang X, Estes MK, Arentzen CJ. Expression of Norwalk virus capsid protein in transgenic tobacco and potato and its oral immunogenicity in mice. Proc Natl Acad Sci U S A 1996;93:5335–40.

Brown CS, Van Lent JW, Vlak JM, Spaan WJ. Assembly of empty capsids by using baculovirus recombinants expressing human parvovirus B19 structural proteins. J Virol 1991;65:2702–6.

Wiedermann U, Wiltshire C, Jasinska J, Kundi M, Zurbriggen R, Garner-Spitzer E, et al. A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu-specific immune responses in patients with metastatic breast cancer: a phase I study. Breast Cancer Res Treat 2010;119:673–83.

De Bernardis F, Amacker M, Arancia S, Sandini S, Gremion C, Zurbriggen R, et al. A virosomal vaccine against candidal vaginitis: immunogenicity, efficacy and safety profile in animal models. Vaccine 2012;30:4490–8.

Leroux-Roels G, Maes C, Clement F, van Engelenburg F, van den Dobbelsteen M, De Bernardis F, Amacker M, Arancia S, Sandini S, Gremion C, Zurbriggen R, et al. A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu-specific immune responses in patients with metastatic breast cancer: a phase I study. Breast Cancer Res Treat 2010;119:673–83.

Smets R, Metcalfe IC. Infliximab V a trivalent virome subunit influenza vaccine: production. Vaccine 2002;20(Suppl 5):B17–23.

Smith D, Gow I, Colebunders R, Wellers I, Tchamouroff S, Weber J, et al. Therapeutic vaccination (p24-VLP) of patients with advanced HIV-1 infection in the pre-HAART era does not alter CD4 cell decline. HIV Med 2001;2:272–5.